Alnylam Pharmaceuticals Inc ALNY:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:34 PM EST
144.32UNCH (UNCH)
Volume
16,195
Close
144.32quote price arrow down-8.09 (-5.31%)
Volume
484,496
52 week range
84.97 - 178.41

...

Loading . . .

KEY STATS

  • Open151.91
  • Day High152.00
  • Day Low143.54
  • Prev Close152.41
  • 52 Week High178.41
  • 52 Week High Date01/26/21
  • 52 Week Low84.97
  • 52 Week Low Date03/13/20
  • Market Cap16.885B
  • Shares Out117.00M
  • 10 Day Average Volume0.53M
  • Dividend-
  • Dividend Yield-
  • Beta1.30
  • 1 Year % Change29.53

RATIOS/PROFITABILITY

  • EPS (TTM)-7.45
  • P/E (TTM)-19.36
  • Fwd P/E (NTM)-21.36
  • EBITDA (MRQ)-793.666M
  • ROE (MRQ)-69.92%
  • Revenue (MRQ)492.85M
  • Gross Margin (MRQ)84.16%
  • Net Margin (MRQ)-174.15%
  • Debt To Equity (MRQ)18.82%

EVENTS

  • Earnings Date05/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Alnylam Pharmaceuticals Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple...
Michael Bonney
Chairman
John Maraganore Ph.D.
Chief Executive Officer
Yvonne Greenstreet
President
Jeffrey Poulton
Chief Financial Officer
Laurie Keating
Executive Vice President
Address
675 W Kendall St
Cambridge, MA
02142-1168
United States